Objective: To determine the proportion of patients diagnosed with cervical cancer or cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) despite testing negative for HPV.
Methods: A prospective study was conducted at a university hospital in Barcelona, Spain, between March 2003 and January 2015 among women with abnormal cytology results according to the Bethesda classification system. All participants underwent HPV testing, cytology, and colposcopy.
Results: Among 1376 participants, 609 (44.3%) were diagnosed with CIN 2/3. Of these women, 74 (12.2%) tested negative for HPV. Among 479 women with colposcopy-guided biopsy sampling showing CIN 2/3, cone biopsy results that were negative for CIN 2/3 were more frequent among patients with negative HPV testing (13/61 [21.3%]) than among those with positive HPV tests (58/418 [13.9%]; P=0.03). Additionally, among 59 patients diagnosed with cervical cancer, 9 (15.3%) tested negative for HPV.
Conclusion: The HPV test was negative for 12% and 15% of patients diagnosed with biopsy-proven CIN 2/3 and cervical cancer, respectively.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ijgo.12030 | DOI Listing |
Sci Total Environ
December 2024
Center for Environmental Measurement and Modeling, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, USA.
Epidemiologic studies of ambient fine particulate matter (PM) and ozone (O) often use outdoor concentrations from central-site monitors or air quality model estimates as exposure surrogates, which can result in exposure errors. We previously developed an exposure model called TracMyAir, which is an iPhone application that determines seven tiers of individual-level exposure metrics for ambient PM and O using outdoor concentrations, home building characteristics, weather, time-activities. The exposure metrics with increasing information needs and complexity include: outdoor concentration (C, Tier 1), building infiltration factor (F, Tier 2), indoor concentration (C, Tier 3), time spent in microenvironments (ME) (T, Tier 4), personal exposure factor (F, Tier 5), exposure (E, Tier 6), and inhaled dose (D, Tier 7).
View Article and Find Full Text PDFInt J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynecology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Objective: To determine the safety, tolerance, and adherence to self-administered intravaginal 5% fluorouracil (5FU) cream as adjuvant therapy following cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) treatment among women living with HIV (WLWH) in Kenya.
Methods: A phase I pilot trial was performed among 12 WLWH in Kenya, aged 18-49 years between March 2023 and February 2024 (ClinicalTrial.gov NCT05362955).
Reprod Biol Endocrinol
December 2024
Department of Cardiology, School of Medicine, Balikesir University, Balikesir, Turkey.
Proc Natl Acad Sci U S A
December 2024
Division of Cancer Etiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China.
There are three distinct forms of autophagy, namely, macroautophagy, microautophagy, and HSPA8 chaperone-mediated autophagy (CMA). While macroautophagy is widely recognized as a regulator of chromosomal instability (CIN) through various pathways, the contributions of CMA and microautophagy to CIN remain uncertain. , a conserved gene in vertebrates, is frequently mutated and down-regulated in numerous human cancers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!